This generally well-conducted review found that telmisartan provided better control of blood pressure than losartan in hypertensive patients without an increased risk of associated adverse events. The review appeared to be generally well conducted, however, the possible presence of publication bias and some clinical heterogeneity should be borne in mind when interpreting the conclusions.
Results of the review
Eleven RCTs were included (n=1,832). Trial size ranged from 40 to 720 patients. Four trials had a Jadad score of 4, three scored 3, one scored 2 and three scored 1. Allocation concealment and intention to treat analysis were the main shortcomings in most studies.
The funnel plot for clinic diastolic blood pressure reduction indicated publication bias but the funnel plot for the therapeutic response of diastolic blood pressure reduction did not.
Telmisartan was associated with a significant reduction in clinic diastolic blood pressure compared with losartan (10 RCTs) WMD 2.62 (95% CI: 0.96, 4.27, p=0.002), but significant heterogeneity was detected I 2 = 80.8% (which became non-significant with the exclusion of one study). Similar reductions were found for systolic blood pressure with telmisartan compared with losartan (10 RCTs) WMD 2.77 (95% CI: 1.90, 3.63, p<0.00001); significant heterogeneity was not indicated. Ambulatory diastolic blood pressure and systolic blood pressure were also significantly reduced for the previous six hours, 24 hours, daytime and night time in patients treated with telmisartan compared with losartan. There was significant heterogeneity in the analysis for diastolic blood pressure for 24 hours, daytime and night time, which again became non-significant when a study was excluded.
There was a significant increase in the therapeutic response with telmisartan compared with losartan in diastolic blood pressure (seven trials) RR 1.14 (95% CI: 1.04, 1.23, p=0.003) and systolic blood pressure (four trials) RR 1.10 (95% CI: 1.01, 1.20, p=0.03). No significant heterogeneity was detected.
No significant differences in withdrawals and adverse events were found with telmisartan compared with losartan.
Results of sensitivity analyses and subgroup analyses were reported in the paper.
Authors' conclusions
Telmisartan provides better control of blood pressure than losartan with no increased risk of adverse events.
CRD commentary
The review question was well defined and supported by inclusion criteria for study design, participants, intervention and outcomes. The search included three appropriate databases, however, the authors did not report any attempts to identify unpublished studies and publication bias was indicated. Language restrictions were not reported, so it was not known whether publications in all languages were sought to reduce the possibility of language bias. Study selection, data extraction and validity assessment were performed in duplicate, reducing the risk of reviewer error and bias. Quality of primary studies was assessed using appropriate criteria and study details reported. Where heterogeneity was detected with pooling of studies this was investigated and the use of meta-analysis appeared to be appropriate. This review appeared to be generally well-conducted and the conclusions were likely to be reliable, although the possible presence of publication bias and some clinical heterogeneity should be borne in mind when interpreting the conclusions.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors stated that RCTs that compare the effects of telmisartan and losartan lasting at least 12 months (preferably more than five years) were needed in adults with mild to moderate hypertension. Outcomes should include clinical and ambulatory blood pressure reductions, blood pressure control, blood pressure response, mortality, cardiaccerebrovascular events and adverse events. Response to telmisartan should be determined in patients that did not adequately respond to losartan.
